Bergman M, Gidez L I, Eder H A
Diabetes Res. 1986 Jun;3(5):245-8.
The effects of glipizide on HDL subclass levels were prospectively evaluated in 7 women and 2 men with non-insulin dependent (Type 2) diabetes. Total HDL, HDL2 and HDL3 levels were unchanged during the treatment period. Baseline HDL levels were lower when compared to a control population which may have been due to the elevated body weight present in most subjects. Mean blood glucose and HbA1 levels were unchanged for the entire group although significant improvement was noted in 5 individuals. Triglyceride and cholesterol levels were not affected by treatment with glipizide. In conclusion, glipizide does not have an adverse affect on HDL lipoprotein levels when patients are followed prospectively.
对7名女性和2名非胰岛素依赖型(2型)糖尿病男性患者进行了前瞻性评估,以研究格列吡嗪对高密度脂蛋白亚类水平的影响。在治疗期间,总高密度脂蛋白、高密度脂蛋白2和高密度脂蛋白3水平均未改变。与对照组相比,基线高密度脂蛋白水平较低,这可能是由于大多数受试者体重升高所致。尽管有5名个体有显著改善,但整个组的平均血糖和糖化血红蛋白水平未改变。甘油三酯和胆固醇水平不受格列吡嗪治疗的影响。总之,对患者进行前瞻性随访时,格列吡嗪对高密度脂蛋白水平没有不良影响。